Pemafibrate

Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.

In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1 mg tablets.

Description

Pemafibrate, marketed as Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.

In 3 July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan. It is available in 0.1 mg tablets.

 

Additional information

CAS Number

Keywords

Molecular Formula

Molecular Weight


Notice: id was called incorrectly. Product properties should not be accessed directly. Backtrace: require('wp-blog-header.php'), require_once('wp-includes/template-loader.php'), include('/plugins/woocommerce/templates/single-product.php'), wc_get_template_part, load_template, require('/plugins/woocommerce/templates/content-single-product.php'), do_action('woocommerce_after_single_product_summary'), WP_Hook->do_action, WP_Hook->apply_filters, woocommerce_output_related_products, woocommerce_related_products, wc_get_template, include('/themes/stout/templates/woocommerce/single-product/related.php'), WC_Abstract_Legacy_Product->__get, wc_doing_it_wrong Please see Debugging in WordPress for more information. (This message was added in version 3.0.) in /var/www/wp-includes/functions.php on line 5313